Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB081776 in advanced malignancies
NCT03522142Phase 1Terminated
- Sponsor
- Incyte
- Start
- Aug 2018
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of INCB081776 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma (HCC) and 9 more (2 arms), sponsored by Incyte. Primary endpoints: Treatment-Emergent Adverse Events, Recommended Dose for Expansion at 1 year and 1 more. Started Aug 2018; status: terminated.
02
Drugs
INCB081776
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomahepatocellular carcinoma (HCC)melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03522142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03522142.